195 related articles for article (PubMed ID: 23653645)
1. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview.
Treglia G; Annunziata S; Muoio B; Salvatori M; Ceriani L; Giovanella L
Int J Endocrinol; 2013; 2013():856189. PubMed ID: 23653645
[TBL] [Abstract][Full Text] [Related]
2. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen in Anaplastic and Poorly Differentiated Thyroid Cancer-A New Diagnostic and Therapeutic Target?
Wächter S; Di Fazio P; Maurer E; Manoharan J; Keber C; Pfestroff A; Librizzi D; Bartsch DK; Luster M; Eilsberger F
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830843
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.
Treglia G; Muoio B; Giovanella L; Salvatori M
Eur Arch Otorhinolaryngol; 2013 May; 270(6):1783-7. PubMed ID: 23053387
[TBL] [Abstract][Full Text] [Related]
5. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
8. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
Salvatori M; Biondi B; Rufini V
Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
10. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.
Abraham T; Schöder H
Semin Nucl Med; 2011 Mar; 41(2):121-38. PubMed ID: 21272686
[TBL] [Abstract][Full Text] [Related]
12. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
13. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
15. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
16. Impact of 18F-FDG PET/CT on Clinical Management of Suspected Radio-Iodine Refractory Differentiated Thyroid Cancer (RAI-R-DTC).
Lodi Rizzini E; Repaci A; Tabacchi E; Zanoni L; Vicennati V; Cavicchi O; Pagotto U; Morganti AG; Fanti S; Monari F
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441364
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
18. Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer.
Matsuo M; Baba S; Hashimoto K; Isoda T; Kitamura Y; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
Anticancer Res; 2023 Jan; 43(1):183-190. PubMed ID: 36585178
[TBL] [Abstract][Full Text] [Related]
19. The Diagnostic Value of
Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
[No Abstract] [Full Text] [Related]
20. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]